Bioinformatics is an interdisciplinary field of science that develops methods and software tools for understanding biological data, especially when the data sets are large and complex. Bioinformatics uses biology, chemistry, physics, computer science, data science, computer programming, information engineering, mathematics and statistics to analyze and interpret biological data. The process of analyzing and interpreting data can sometimes be referred to as computational biology, however this distinction between the two terms is often disputed. To some, the term computational biology refers to building and using models of biological systems.
Genomics is an interdisciplinary field of molecular biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.
A DNA sequencer is a scientific instrument used to automate the DNA sequencing process. Given a sample of DNA, a DNA sequencer is used to determine the order of the four bases: G (guanine), C (cytosine), A (adenine) and T (thymine). This is then reported as a text string, called a read. Some DNA sequencers can be also considered optical instruments as they analyze light signals originating from fluorochromes attached to nucleotides.
Agilent Technologies, Inc. is an American global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting IPO of Agilent stock was the largest in the history of Silicon Valley at the time. From 1999 to 2014, the company produced optics, semiconductors, EDA software and test and measurement equipment for electronics; that division was spun off to form Keysight. Since then, the company has continued to expand into pharmaceutical, diagnostics & clinical, and academia & government (research) markets.
Avadis "Avie" Tevanian is an American software engineer. At Carnegie Mellon University, he was a principal designer and engineer of the Mach operating system. He used that work at NeXT Inc. as the foundation of the NeXTSTEP operating system. He was senior vice president of software engineering at Apple from 1997 to 2003, and then chief software technology officer from 2003 to 2006. There, he redesigned NeXTSTEP to become macOS. Apple's macOS and iOS both incorporate the Mach Kernel, and iPadOS, watchOS, and tvOS are all derived from iOS. He was a longtime friend of Steve Jobs.
Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name. The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.
DNA sequencing is the process of determining the nucleic acid sequence – the order of nucleotides in DNA. It includes any method or technology that is used to determine the order of the four bases: adenine, guanine, cytosine, and thymine. The advent of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery.
Jay M. Short is founder and CEO of the antibody drug company BioAtla, LLC. He was vice president of research and operations at Stratagene, president of the Stratagene antibody subsidiary Stratacyte, then founder and CEO of Diversa until 2005. While at Diversa, Short invented methods of protein and pathway discovery via metagenomics, in addition to evolution technologies gene site saturation mutagenesis (GSSM) and GeneReassembly, and was the first to combine these discovery and evolution technologies.
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in respectively Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer (CEO).
Anthony James Cuticchia Jr. was an American scientist with expertise in the fields of genetics, bioinformatics, and genomics. In particular, he was responsible for the collection of the data constituting the human gene map, prior to the final sequencing of the genome. He was also a practicing attorney. He died due to cancer on January 6, 2022.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.
Thermo Fisher Scientific Inc. is an American life, science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Applied Biosystems is one of various brands under the Life Technologies brand of Thermo Fisher Scientific corporation. The brand is focused on integrated systems for genetic analysis, which include computerized machines and the consumables used within them.
Objective Systems Integrators (OSI) is a multinational computer technology corporation that develops, manufactures, licenses, and supports software products which automate the monitoring, control, delivery, and management of services for multinational corporation service providers including:
Gajendra Pal Singh Raghava is an Indian bio-informatician and head of computational biology at the Indraprastha Institute of Information Technology.
Nuvelo Inc. was a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. On January 27, 2009, the company was acquired by ARCA Biopharma, Inc. in a reverse takeover transaction.
Knome, Inc. was a human genome interpretation company based in Cambridge, Massachusetts. Launched in 2007, Knome focused on improving quality of life by applying insights gained from the interpretation of human genomes. They helped identify and classify the variants, genes, and gene sets that are likely to govern or underlie a specific disease, tumor, or drug response. Their clients included academic, pharmaceutical and medical researchers. In 2015, it was acquired by Tute Genomics.
Stratagene California was an American biotechnological company based in La Jolla, California, a maker of life science research and diagnostic products. It was established in 1984 and incorporated in California. It has been involved with the fields of cellular analysis, cloning, cytogenomics, DNA methylation and DNA Sizing and Quantification and food testing. In 2007, Agilent Technologies acquired Stratagene for $250 million, spinning off certain business assets and licensing certain molecular diagnostics technology to a new entity, Decisive Diagnostics. As of October 2011, the Chief Executive of the new company is Joseph Sorge, original founder and CEO of Stratagene.
Tute Genomics is a genomics startup that provides a cloud-based web application for rapid and accurate annotation of human genomic data. Built on the expertise of ANNOVAR, Tute assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Based in Provo, Utah, Tute was co-founded by Dr. Kai Wang, an Assistant Professor at the University of Southern California (USC); and Dr. Reid J. Robison, a board-certified psychiatrist with fellowship training in both neurodevelopmental genetics and bioinformatics.
